

2015 Strategies in the Japanese Hospital Tumor Marker Testing Market

https://marketpublishers.com/r/2F1447CC371EN.html

Date: February 2015

Pages: 537

Price: US\$ 3,880.00 (Single User License)

ID: 2F1447CC371EN

Abstracts

This new report from VPGMarketResearch contains 537 pages, 42 tables, and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including:

Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in Japanese hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in



R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 537 pages and 42 tables



Contents

Introduction

Worldwide Market and Technology Overview

- A. Cancer Statistics and Etiology
- 1. BREST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEMIA
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SKIN CANCER
- 10. UTERINE CANCER
- 11. OVARIAN CANCER
- 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
- 1. INTRODUCTION
- 2. TUMOR MARKER CLASSIFICATION
- 3. ACTH
- 4. ALPHA-FETOPROTEIN (AFP)
- 5. BETA-2 MICROGLOBULIN
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. CALCITONIN
- 10. CARCINOEMBRIONIC ANTIGEN (CEA)
- 11. ESTROGEN AND PROGESTERONE RECEPTORS
- 12. FERRITIN
- 13. GASTRIN
- 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
- 15. INSULIN
- 16. NSE
- 17. OCCULT BLOOD
- 18. PAP SMEAR/HPV
- 19. PROSTATIC ACID PHOSPHATASE (PAP)



- 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
- 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
- 22. T AND B LYMPHOCYTES
- 23. TDT
- 24. THYROGLOBULIN
- 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
- 26. BIOCHEMICAL TUMOR MARKERS

ADA

B-Protein

PNP

5'-Nucleotidase

27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR



Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING TUMOR MARKERS

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18



DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opiod Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

C. Instrumentation Review And

Market Needs

- 1. ABBOTT AXSYM
- 2. ABBOTT ARCHITECT C4000
- 3. ABBOTT ARCHITECT I200 SERIES
- 4. ABBOTT ARCHITECT CI820 SYSTEM
- 5. BECKMAN COULTER UNICEL SERIES
- 6. BECKMAN COULTER ACCESS
- 7. BINDING SITE ESP600



- 8. BIOMERIEUX MINI VIDAS
- 9. CAROLINA CHEMISTRIES BIOLIS 24I
- 10. DIASORIN LIAISON
- 11. HORIBA ABX PENTRA
- 12. INVERNESS DS2
- 13. J&J VITROS ECI/ECIQ
- 14. J&J VITROS 3600
- 15. J&J VITROS 5600
- 16. OLYMPUS AU5400
- 17. OLYMPUS AU3000I
- **18. OLYMPUS AU2700**
- 19. ROCHE MODULAR ANALYTICS
- 20. ROCHE COBAS INTEGRA
- 21. ROCHE COBAS INTEGRA 40 PLUS
- 22. ROCHE ELECSYS
- 23. ROCHE COBAS C311
- 24. SIEMENS ADVIA CENTAUR
- 25. SIEMENS DIMENSION
- 26. SIEMENS DIMENSION RXL MAX
- 27. SIEMENS DIMENSION VISTA
- 28. SIEMENS IMMULITE
- 29. SIEMENS STRATUS
- 30. TOSOH AIA-SERIES
- 31. VITAL DIAGNOSTICS ATAC 8000
- 32. VITAL DIAGNOSTICS ENVOY
- D. Current and Emerging Technologies
- 1. MONOCLONAL AND POLYCLONAL ANTIBODIES
- 2. IMMUNOASSAYS
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence



Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- H. Affinity Chromatographu
 - e. Liposome Flow-Injection Immunoassay
- 3. MOLECULAR DIAGNOSTICS
 - a. Technology Overview
- b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

- 3 SR, and others
- 4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas

Lymphoid Malignancies

- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. ARTIFICIAL INTELLIGENCE
- 6. FLOW CYTOMETRY
- 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
- 8. BIOSENSORS
- 9. COMPETING/COMPLEMENTING TECHNOLOGIES
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy



E. Personal Testing

Japan

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
- 1. MARKETING APPROACHES
- 2. PRODUCT COMPLEXITY
- 3. CUSTOMER PREFERENCE
- 4. ESTABLISHED SUPPLIERS
- 5. EMERGING SUPPLIERS
- 6. MAJOR TYPES OF DISTRIBUTORS
- 7. MARKET SEGMENTATION FACTOR

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- **B.** Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection



F. Regulatory Constraints

G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott

AdnaGen

Applied Gene Technologies

Arca

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

Kreatech

Kyowa Medex

Life Technologies

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

Otho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics



Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

APPENDIXES

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic

Technology and Applications

Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Sub classification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: Japan, Hospital Cancer Diagnostic Test Volume and Sales Forecast

Japan, Estimated Cancer Death Rates Per 100,00 Population

Japan, Hospital Laboratories Performing Cancer Diagnostic Tests

Japan, Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size

Japan, Hospital Laboratories Major

Cancer Diagnostic Test Volume Forecast by Test



Japan, Hospital Laboratories Cancer Diagnostic Sales Forecast by Test Japan, Total Cancer Diagnostics Sales by Major Supplier Japan, AFP Testing Market Diagnostics Sales by Major Supplier Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier Japan, PAP Testing Market Diagnostics Sales by Major Supplier Japan, PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2015 Strategies in the Japanese Hospital Tumor Marker Testing Market

Product link: https://marketpublishers.com/r/2F1447CC371EN.html

Price: US\$ 3,880.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2F1447CC371EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms